RxDoctor Payments Data

Mario Binder, MD

Cardiovascular Disease · Anchorage, AKNPI 1265457022

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 27.4% of the total.

$1,924in general payments, 2019–2025

Across 84 payments — averaging $22.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$528
  • Amgen$359
  • Novartis$329
  • Pfizer$298
  • Bard Peripheral Vascular, Inc.$98
  • Genentech USA, Inc.$87
  • plus $226 from 10 others

What the payments were for

  • Food & beverage$1,924100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,924 in reported general payments places this provider in the 75th percentile of 26 cardiovascular disease providers in Alaska.

See all cardiovascular disease providers in Alaska

Medicare billing

Part B allowed, 2024
$346,417
Medicare patients
1,385
Services billed
4,803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban285$418,868
EntrestoSacubitril/Valsartan84$128,186
XareltoRivaroxaban102$112,741
Repatha SureclickEvolocumab84$99,717
BrilintaTicagrelor19$21,575
FarxigaDapagliflozin Propanediol13$15,155
Praluent PenAlirocumab11$11,942
Metoprolol Succinate677$11,093
Carvedilol ErCarvedilol Phosphate14$9,049
Atorvastatin Calcium655$8,152
Losartan Potassium342$4,889
Rosuvastatin Calcium208$4,575
ClopidogrelClopidogrel Bisulfate154$3,443
Clonidine16$3,083
Candesartan Cilexetil17$2,955

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$298$418,868285 claims
NovartisEntresto$329$128,18684 claims
Johnson & JohnsonXarelto$39$112,741102 claims
AstraZenecaBrilinta, Farxiga$16$36,72932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 26 cardiovascular disease providers in Alaska.

Other cardiovascular disease in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →